Condition: Colorectal Cancer · Esophagus Cancer · Gastric Cancer · Sponsor: Chongqing Precision Biotech Co., Ltd
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA positive late malignant solid tumors, and explore the applicable dose regimen for phase II clinical trials.
This description comes directly from the study's public registry record.
Ying Yuan, M.D · 13858193601 · yuanying1999@tom.com
Weijia Fang, M.D · 13758211655 · weijiafang@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06043466